• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a solution for preserving placental blood cells, bone marrow and peripheral blood, said solution being injectable.
    公开号:FR3040860A1
    申请号:FR1558409
    申请日:2015-09-10
    公开日:2017-03-17
    发明作者:Zoran Ivanovic；Jean Chevaleyre；Laura Rodriguez；Esther Attebi
    申请人:Francais du Sang Ets；
    IPC主号:
    专利说明:

    INJECTABLE CONSERVATION MEDIUM FOR THE CONSERVATION OF PLACENTAL BLOOD CELLS, BONE MARROW AND PERIPHERAL BLOOD
    Field of the invention
    The present invention relates to the medical field, and in particular to the conservation media of placental blood cells, bone marrow and peripheral blood.
    Context of the invention
    Placental blood stem cells are an alternative to bone marrow transplantation. Patients without a matching compatible donor or registered on the national bone marrow donor file can then benefit from the transplantation of one or two units of placental blood. The advantage of this alternative is that these cells thus make it possible to evade the requirement of a very high level of HLA compatibility between the patient and the graft cells.
    Between the steps taken to collect and freeze placental blood units, current recommendations stipulate a delay of only 24 hours because the viability and functionality of stem cells and progenitors decreases at 4 ° C. The extension of this period would allow to take units of placental blood at the weekend but also to lengthen the distance between the place of sampling and the place of storage.
    In addition, the ex vivo amplification of CD34 + cells, particularly those of placental blood, has been developed over the past 15 years (Duchez et al, 2003, J Hematother Stem Cell Res, 12, 587-9, Duchez et al. , 2012, Cell Transplant, 21, 2517-21, Ivanovic et al, 2004, Stem Cells, 22, 716-24, Ivanovic et al, 2006, Transfusion, 46, 126-31, Ivanovic et al, 2011, Cell Transplant, Polini et al., 1997, Hematol Cell Ther, 39, 49-58, Boiron et al, 2006, Transfusion, 46, 1934-42, Milpied et al, 2009, ASH Meeting abstracts, Blood, 114, Abst 502, p 207). It makes it possible to constitute hematopoietic grafts having two advantages: to maintain the potential of graft in the long term and to reduce the period of aplasia post conditioning.
    The clinical phase of the GRAPA (Allogenic Grafted Amplified Progenitor) protocol for ex vivo expansion of CD34 + placental blood cells has shown the therapeutic value of this technology, which allows long-term regeneration of medullary cells while shortening the period of time. aplasia post transplant (Milpied et al, supra).
    However, for the preparation of the grafts, the cells contained in a non-injectable culture or culture medium are washed and then resuspended in a solution of human albumin 4% to be injected to patients within 6 hours, which allows only short haul (less than 50 kilometers). Longer periods are associated with a significant loss of functionality of committed progenitors and HSCs (Duchez et al, 2013, Cell Transplant, 22,1501-6).
    Studies have shown the possibility of correctly preserving these cells after culturing for 48 h at + 4 ° C. in a preservation medium (HP02 medium, Macopharma) not injectable to humans (Duchez et al, supra). To the inventors' knowledge, this is the only known medium with such a capacity. However, this medium is non-injectable and washing is necessary before the transplant.
    Most solutions for the preservation of human cells or organs are not injectable because they contain non-Codex-encoded molecules. These molecules are not registered because they have no therapeutic interest, they do not interest pharmaceutical suppliers or they have a toxicity for patients. For example and non-exhaustively, the media include polyethylene glycol, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), sodium erythorbate, glutathione, superoxide dismutase, a catalase, a polysaccharide selected from lactobionate, sucrose, raffinose and trehalose, a phosphate buffer (in particular Na2PO4, K2PO4, NaHPO4, or KHPO4), HEPES buffer and ketoglutarate.
    The establishment of regional, national or even more international centers of competence for this type of production and / or cellular storage requires the ability to transport over long distances, inside Europe or even on other continents. , these grafts properly preserved and inject them without having to wash them. Indeed, washing involves relatively long manipulations requiring dedicated equipment and personnel.
    In this context, it is therefore necessary to have an injectable preservation medium. Summary of the invention
    The present invention provides a preservation solution that is injectable and has good cell preservation and functionality for at least 48 hours.
    Thus, it relates to an injectable solution for storing placental blood cells, bone marrow and peripheral blood, the solution comprising a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, bicarbonate of sodium, vitamin E and / or A, and human albumin. Preferably, it comprises at least 5 g / l of human albumin and 0.0000255 g / l of vitamin E and / or 0.0000026 g / l of vitamin A.
    Optionally, the solution may further comprise lactate and vitamin C. In this embodiment, it contains at least 0.0003125 g / l of vitamin C.
    The solution may also further comprise one or more elements selected from amino acids including glutamine, glucose, mannitol, and citric acid.
    In a preferred embodiment, the injectable solution comprises or consists essentially of a physiological solution of sodium chloride, human albumin, vitamins E, C and A, amino acids including glutamine, potassium and magnesium ions, glucose, mannitol, lactate, sodium bicarbonate and citric acid.
    The present invention also relates to a kit comprising the injectable preservative solution of the present invention and a sterile container for receiving placental blood, bone marrow and peripheral blood cells.
    It further relates to a sterile container for receiving placental blood, bone marrow and peripheral blood cells comprising the injectable preservative solution of the present invention. Optionally, the container may further include placental blood, bone marrow, and peripheral blood cells. Preferably, the cells comprise CD34 + cells.
    The present invention relates to the use of the injectable solution according to the present invention, a kit according to the present invention or a container according to the present invention for storing cells of placental blood, bone marrow and blood. peripheral, preferably in moderate hypothermia, especially at 4 ° C. Preferably, the cells comprise CD34 + cells.
    Finally, the present invention relates to a method for preserving placental blood, bone marrow and peripheral blood cells, comprising contacting the placental blood, bone marrow and peripheral blood cells with the injectable solution according to the present invention. present invention. Preferably, the cells comprise CD34 + cells.
    Detailed description of the invention
    The present invention therefore relates to a solution for preserving placental blood cells, bone marrow and peripheral blood, this preservation solution being injectable. Placental, bone marrow and peripheral blood cells may be native (after collection), thawed or amplified ex vivo. Thus, by "injectable solution for storing cells of the placental blood, bone marrow and peripheral blood" is understood that the solution is adapted to an injection and adapted to the preservation of said cells.
    By "injectable" is understood in the present application that the preservation solution is suitable for an injection (for example intravenous, intramuscular, subcutaneous, etc ...) to a human, without prior rinsing of the cells. Thus, the solution includes only elements admitted or approved as "injectable" by drug authorization authorities such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the National Safety Agency. medicines and health products (ANSM). Thus, it does not include any non-admitted or non-approved element as "injectable" by Drug Authorization Authorities such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the National Agency. safety of medication and health products (ANSM). In particular, the VIDAL® dictionary (2015 edition) can be consulted to determine if an element is approved or admitted as "injectable".
    The reference medium used for the development of the injectable preservative solution according to the present invention is Maco Pharma's HP02 medium (also called MC01). The composition of this medium is secret. However, the patent application WO2014 / 057220 describes component elements (page 13, line 25 - page 14, line 4). This medium is clearly non-injectable. In particular, it comprises HEPES buffer and sodium pyruvate, both not approved as injectables.
    The preservation medium according to the present invention has a preservation efficiency equivalent to this HP02 reference medium, while being injectable. In particular, it allows storage for at least 48 h at 4 ° C, and even 72 h, maintaining viability and functionality of the stem and progenitor cells compatible with a therapeutic use.
    The preservation solution according to the present invention comprises a physiological solution (in particular sodium chloride), human albumin and vitamin E. Alternatively, the preservation solution according to the present invention comprises a physiological solution (in particular sodium chloride), human albumin and vitamin A, the latter having a role similar to that of vitamin E. Human albumin plays an important role in its role of stabilizing the environment, especially under accelerated aging at 37 ° C. Human albumin is commercially available in injectable quality, in particular by the company Baxter or under the names Albunorm®, Flexbumin®, Vialebex® or Ydralbum®. The solution comprises at least 1 g / l of albumin, and preferably at least 5, 10 or 15 g / l. The amount of human albumin in the solution may be between 1 and 100 g / l of solution, preferably between 5 and 40 g / l of solution, even more preferably between 5 and 20 g / l, and more particularly 15 g / l of solution. Expressed otherwise, the solution comprises from 0.1 to 10% human albumin, preferably from 0.5 to 4%, still more preferably from 0.5 to 2%, and most preferably 1.5%.
    The solution also comprises vitamin E and or vitamin A. Preferably, the solution comprises at least vitamin E. Surprisingly, the inventors have indeed discovered that vitamin E (alpha-tocopherol) has a very important effect on cell preservation, especially on their functionality. Vitamin E has even been identified by inventors as the element that has the most important action. The solution comprises at least 0.0000255 g / l of vitamin E. The amount of vitamin E in the solution may especially be between 0.0001 and 0.01 g / l of solution, preferably between 0.001 and 0.006 g / l. solution, and especially 0.004 g / l of solution. This product is commercially available in injectable quality, in particular by Nepalm.
    Preferably, the solution further comprises vitamin C. The solution then comprises at least 0.000312 g / vitamin C. The amount of vitamin C in the solution is between 0.0005 and 0.15 g / l of solution, preferably between 0.001 and 0.1 g / l of solution, and most preferably 0.05 g / l of solution. This product is commercially available in injectable quality, especially in the form of Vitamin C Aguettant.
    Preferably, the solution further comprises vitamin A. The solution then comprises at least 0.0000026 g / l of vitamin A. The amount of vitamin A in the solution is between 0.0001 and 0.001 g / l of solution preferably between 0.0002 and 0.0008 g / l of solution, and most preferably 0.0004 g / l of solution. This product is commercially available in injectable quality, in particular by Nepalm.
    In a particular embodiment, the solution comprises vitamins E and C, vitamins E and A, or vitamins E, C and A. In particular, the vitamins can be made to the solution according to the present invention by adding a cocktail of vitamins available commercially and adapted to an injection. For example and non-exhaustively, the vitamin cocktail may be Cervenit® Baxter which includes retinol palmitate, cholecalciferol, alpha-tocopherol, ascorbic acid, thiamine, riboflavin pyridoxine, cyanocobalamin, folic acid, pantothenic acid, biotin and nicotinamide; or Vitalipide® by Fresenius Kabi which includes retinol palmitate, alpha-tocopherol, vitamin D2 and vitamin K1.
    The physiological solution is conventionally a solution of sodium chloride, in particular at 0.9%. This is present in the solution in physiologically acceptable amounts. Preferably, the sodium chloride may be contained in an amount of between 5 and 7 g / l, and preferably about 6 g / l.
    Preferably, the solution according to the present invention further comprises potassium (K +) and magnesium (Mg 2+) ions, preferably in physiological amount. In particular, the solution comprises potassium chloride, preferably in physiological amount (i.e., about 0.33 g / l). It also comprises magnesium sulphate, preferably in an amount of between 0.01 and 3 g / l, preferably between 0.05 and 2.4 g / l, especially around 0.1 g / l. The solution may further include calcium ions.
    The preservation solution according to the present invention may further comprise sodium bicarbonate. Preferably, it is contained in the solution in an amount of between 0.1 and 4.5 g / l, preferably between 0.25 and 4.15 g / l, and especially about 0.52 g / l. This product is commercially available in injectable quality.
    The preservation solution according to the present invention may further comprise lactate, in particular Ringer's lactate. This product is commercially available in injectable quality, in particular by the companies Macopharma, Fresenius Kabi or Baxter. Ringer lactate is present in the solution so that the sodium lactate is between 0.1 and 3 g / l, preferably 0.2 and 2.7 g / l, and in particular about 0.7 g / l.
    The preservation solution according to the present invention may further comprise citric acid, in particular ACD A (citric acid, citrate, dextrose, solution A).
    Preferably, the solution according to the present invention further comprises amino acids. The amino acids may be present in amounts of between 1 and 4 g / l, preferably between 1.3 and 3.3 g / l, especially about 2 g / l. Several amino acid cocktails are commercially available in injectable quality, for example Vaminolact® from Fresenius Kabi. Among the amino acids, it is advantageous for the solution to contain glutamine, especially in amounts of glutamine of between 0.2 and 0.8 g / l, preferably between 0.3 and 0.7 g / l, and in particular about 0.7 g / l. Glutamine intake can be achieved by commercially available products for injection such as Fresenius Kabi's Dipeptiven®.
    The preservation solution according to the present invention may further comprise glucose. It is conventionally used in an amount of about 1 g / l.
    The preservation solution according to the present invention may further comprise mannitol. For example, mannitol may be between 1 and 25 g / l, preferably between 5 and 20 g / l, and in particular about 5 g / l.
    Thus, in alternative embodiments, the injectable preservative solution of the present invention comprises or consists essentially of: a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamin E; a saline solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamin A; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamins E and C; a saline solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamins A and C; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamins E and A; a physiological solution of sodium chloride, potassium chloride, magnesium sulphate, sodium bicarbonate, human albumin and vitamins E, C and A; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin, vitamin E and one or more components selected from the group consisting of lactate, amino acids including glutamine, glucose, mannitol, and citric acid; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin, vitamin A and one or more components selected from the group consisting of lactate, amino acids including glutamine, glucose, mannitol, and citric acid; physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin, vitamins E and C, and one or more components selected from the group consisting of lactate, amino acids including glutamine, glucose, mannitol, and citric acid; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin, vitamins A and C, and one or more components selected from the group consisting of lactate, amino acids including glutamine, glucose, mannitol, and citric acid; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin, vitamins E and A, and one or more components selected from the group consisting of lactate, amino acids including glutamine, glucose, mannitol, and citric acid; a physiological solution of sodium chloride, potassium chloride, magnesium sulfate, sodium bicarbonate, human albumin and vitamins E, C and A, and one or more components selected from the group consisting of lactate amino acids including glutamine, glucose, mannitol, and citric acid.
    Preferably, each component is present in the amounts indicated in the table below.
    Table 1
    By "essentially consists of" it is understood that the solution may comprise components other than those listed, but in an amount of less than 10% by weight, preferably less than 5, 4, 3, 2 or 1%. It is understood that these other components are compatible with an injection.
    In a most preferred embodiment, the preservation solution according to the present invention comprises human albumin, amino acids, potassium chloride, glucose, glutamine, magnesium sulfate, vitamins E, C and A, mannitol, lactate, preferably lactated Ringer, sodium chloride, sodium bicarbonate and citric acid, particularly in the form of ACD A.
    By "about" is meant more or less 10%, preferably plus or minus 5%. For example, about 10 is between 9 and 11, and preferably between 9.5 and 10.5.
    Thus, the preservation medium according to the present, to be injectable, does not contain any element not authorized by the drug administration agencies, in particular the FDA, the ANSM and ΙΈΜΑ. In particular, the preservation solution according to the present invention does not contain one or more elements selected from the group consisting of polyethylene glycol, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) , sodium erythorbate, glutathione, a superoxide dismutase, a catalase, a polysaccharide in particular selected from lactobionate, sucrose, raffinose and trehalose, a phosphate buffer (in particular Na2PC> 4, K2PO4, NaHPC> 4 , or KHPO4), and ketoglutarate. In a preferred embodiment, the solution does not include any of the elements of this list. In a preferred embodiment, the preservative injectable solution according to the present invention does not include phenol red, iron gluconate, human insulin and / or nucleosides. In a preferred embodiment, the preservation medium according to the present invention does not include a vanadium compound such as oxovanadium, bis (maltolato) oxovanadium and orthovanadium.
    The present invention is therefore related to the use of the injectable preservative solution according to the present invention for storing placental blood, bone marrow and peripheral blood cells, particularly CD34 + cells.
    The present invention also relates to a kit comprising the injectable preservative solution of the present invention and a sterile container for receiving placental blood, bone marrow and peripheral blood cells, particularly CD34 + cells. It also relates to a sterile container for receiving placental blood, bone marrow and peripheral blood cells containing the injectable preserving solution of the present invention. Finally, it relates to the use of a kit or container containing the injectable preserving solution according to the present invention for preserving placental blood, bone marrow and peripheral blood cells, in particular CD34 + cells.
    The sterile container is made with an air barrier film and / or arranged in a package made with an air barrier film. The air barrier film is an oxygen barrier film or a barrier to oxygen and carbon dioxide. The film can be made of PVC (polyvinyl chloride). It may alternatively comprise an ethylene-vinyl alcohol copolymer (EVOH), a vinylidene chloride copolymer, polyvinyl alcohol, polyacrylonitrile, an ethylene vinyl acetate copolymer (EVA) or polyamide. In a preferred embodiment, the container is made of a film comprising EVA or PVC. In particular, the air barrier film has a multilayer structure such as a tri-layer structure whose central layer is air barrier material. The central layer is sandwiched between two layers of another material such as a polyolefin, especially polyethylene, polypropylene or an ethylene-olefin copolymer. For example, the film is a three-layer film of ethylene-vinyl acetate / ethylene-vinyl alcohol / ethylene-vinyl acetate (EVA / EVOH / EVA).
    The present invention also relates to a method of preserving placental blood, bone marrow and peripheral blood cells comprising contacting said cells with the injectable preservative solution of the present invention. Preferably, the cells comprise CD34 + cells. It also relates to a method of preserving CD34 + cells comprising contacting these cells with the injectable preservation solution according to the present invention.
    Preferably, the preservation solution is brought into contact with the cells with a volume ratio of between 1: 0.5 and 1: 2. This ratio is particularly relevant for the sampling of placental blood, bone marrow and peripheral blood. . On the other hand, as regards the mononuclear cells, the fresh or thawed CD34 + cells, in particular those selected from the placental blood, bone marrow and peripheral blood samples, as well as the cells obtained after ex vivo amplifications, are postponed. in suspension in the preservation solution at variable cell concentrations according to the protocols and the necessities.
    Preferably, the cells are stored at a temperature between 0 ° C and 10 ° C and preferably about 4 ° C.
    The present invention also relates to a sterile container for receiving placental, bone marrow and peripheral blood cells containing the injectable preservative solution of the present invention and placental blood, bone marrow and peripheral blood cells. . Preferably, the cells comprise CD34 + cells. It also relates to a sterile container for receiving CD34 + cells containing the preservative solution for injection according to the present invention and CD34 + cells. Thus, the container may be optionally considered to contain a graft ready for injection.
    Preferably, the cells are mammalian cells, and most preferably human cells. In particular, the cells are not embryonic human cells.
    The cells to be conserved are cells as collected or optionally as obtained after expansion ex vivo. The cells of particular interest are CD34 + cells, and more specifically hematopoietic stem cells and progenitor cells.
    In a preferred embodiment, the cells to be conserved are placental blood cells.
    The cells to be conserved may be cells directly removed, cells obtained by ex vivo cell amplification, or cells that have been frozen.
    According to a preferred embodiment, the cells are cells intended to be transplanted into a recipient and are preferably derived from a sample from a donor. The donor and the recipient may be the same individual (autologous transplant) or different individuals (allogeneic transplant).
    The present invention also relates to a graft comprising cells for transplantation and the injectable preservative solution of the present invention. Preferably, the cells to be transplanted are placental blood, bone marrow and peripheral blood cells. In particular, the cells comprise CD34 + cells.
    The present invention also relates to a method of treating a patient comprising injecting the graft as defined above. The injection may be an intravenous, subcutaneous, intramuscular injection including intracardiac injection.
    All references cited in this specification are incorporated by reference in this application. Other features and advantages of the invention will appear better on reading the following examples given for illustrative and non-limiting.
    Description of figures
    Figure 1. Preservation yield of amplified placental blood CD34 + cells, stored 48 h at 4 ° C (n = 12). For each condition, on the left, the CNT yield (viable nucleated cells) and on the right the CFU (colony forming unit) yield for evaluating the clonogenic functionality. The conditions tested are as follows: J10 (at the end of culture), HSA 4% (medium comprising human serum albumin at 4%), HPO 2 (reference medium of Maco Pharma), Formula 12 components (as described in the examples in Table 2), without HSA (medium Formula 12 without human serum albumin), without Vit C, E, A (Cernevit®) (medium Formula 12 without Cernevit®), lives only C (medium Formula 12 without Cernevit® and Vitamin C), lives E alone (Medium Formula 12 without Cernevit® and Vitamin E), and lives on A alone (Formula 12 medium without Cernevit® and Vitamin A). Outside J10, the other measurements were made after 48 hours of storage of the cells at 4 ° C. The tests were carried out in gas impermeable containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air).
    Figure 2. Preservation of placental blood units after sampling, CFU (n = 9). J1, J3 and J7 correspond respectively to a storage of 1, 3 or 7 days at 4 ° C. PVC corresponds to a storage in a PVC bag, PVC NaCl includes the addition of sodium chloride 0.9%, SEC PVC includes the addition of SEC medium as described in the examples in Table 2.
    Figure 3. Preservation yield of amplified placental blood CD34 + cells, storage 72 h at 4 ° C (n = 11). For each condition, on the left, the CNT yield (viable nucleated cells) and on the right the CFU (colony forming unit) yield for evaluating the clonogenic functionality. The conditions tested are as follows: J10 (at the end of culture); M8 NaCl (medium comprising human serum albumin, amino acids, potassium chloride, glucose, glutamine, sodium bicarbonate, ACD A and NaCl 0.9%) without or with addition of Cernevit®; M8 RL (medium comprising human serum albumin, amino acids, potassium chloride, glucose, glutamine, sodium bicarbonate, ACD A, and Ringer Lactate in place of 0.9% NaCl) without or with the addition of Cernevit®; M8 NaCI without HSA (M8 NaCI devoid of human serum albumin) without or with addition of Cernevit®; M8 NaCl without AA (M8 NaCI lacking amino acids) without or with addition of Cernevit®; M8 NaCI without KCI (M8 NaCI devoid of KCI) without or with addition of Cernevit®; M8 NaCI without GG (M8 NaCI devoid of glucose and glutamine) without or with addition of Cernevit®; M8 NaCI without AAGG (M8 NaCI devoid of amino acids, glucose and glutamine) without or with addition of Cernevit®; SEC 4 NaCl (mileu formula 12 components without
    Ringer Lactate); SEC 4 RL (middle formula 12 components without NaCl 0.9%); HP02 (reference medium of Maco Pharma). The tests were carried out in gas impermeable containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air).
    Figure 4. Preservation yield of amplified placental blood CD34 + cells, storage 72 h at 4 ° C (n = 9). For each condition, on the left, the CNT yield (viable nucleated cells) and on the right the CFU (colony forming unit) yield for evaluating the clonogenic functionality. The conditions tested are as follows: J10 (at the end of culture); HP02 (reference medium of Maco Pharma); SEC (SEC medium as described in the examples in Table 2); without Mg and Mann (SEC medium but without magnesium and mannitol); without magnesium (SEC medium but without magnesium); without Mannitol (SEC medium but without mannitol). The tests were carried out in gas impermeable containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air).
    Figure 5. Preservation yield of amplified placental blood CD34 + cells, stored for 48 h at 4 ° C (n = 9). For each condition, on the left, the yield CNT (viable total nucleated cells) and on the right the yield CFU (colony forming unit) make it possible to evaluate the clonogenic functionality. The conditions tested are as follows: J10 (at the end of culture); HP02 (reference medium of Maco Pharma); Standard SEC (HSA0.5%) (SEC medium as described in the examples in Table 2); SEC Mannitol (low in NaCl) (middle formula 12 components without NaCl 0.9% replaced by an identical volume of mannitol 4.55% [300 mos]); SEC Glucose (low in NaCl) (middle formula 12 components without NaCl 0.9% replaced by an identical volume of 5% glucose solution); SEC HSA 3% (SEC medium as described in the examples in Table 2 but with 3% human serum albumin); SEC PVC bag (here the container is a sampling bag of 20ml PVC permeable to gases) The tests were carried out in gas-tight containers (2.5ml polypropylene tubes of capacity with 2.5ml of cell suspension for avoid the presence of air as much as possible except the PVC bag.
    Figure 6. Preservation yield of amplified placental blood CD34 + cells stored 48h at 4 ° C (n = 8) during the study of a range of volumes of CERNEVIT (and therefore a range of molarity of vitamin E) added to the SEC medium "base" consisting of 11 other components. The conditions tested are as follows: Human albumin (HSA 4%); HP02 (MACOPHARMA reference medium); SEC "base" without CERNEVIT®; then SEC "base" supplemented with decreasing volumes of CERNEVIT® namely: 10ml / l for 45μΜ of vit E; 5 ml / l for 22.5μΜ of vit E; 2 ml / l for 9 μl of vit E; lml / l for 4.5μΜ of vit E; 0.5ml / l for 2.25μΜ of vit E; 0.2ml / l for 0.9μΜ of vit E; 0.1ml / l for 0.45μΜ of vit E; 0.05ml / l for 0.225μΜ of vit E; 0.025ml / l for 0.112μΜ of vit E. The tests were carried out in gas-impermeable containers (2.5ml polypropylene tubes of capacity with 2.5 ml of cell suspension to avoid the presence of air as much as possible).
    Figure 7. Preservation yield of the clonogenicity of mononuclear cells (MNC) and CD34 + cells (after immunomagnetic selection) of mobilized peripheral blood after 48 hours and 120 hours of storage at 4 ° C (n = 1). The CMN cells, after thawing and removal of the cryoprotectant, are separated into 2 aliquots, one of which is resuspended in SEC medium (formulation described as 12 components) and the other treated by immunomagnetic selection to obtain CD34 + cells of purity greater than 80%. are suspended in the same SEC medium (formulation described 12 components). The tests were carried out in gas-tight containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air)
    Figure 8. Preservation yield of the clonogenicity (CFU) of the amplified CD34 + cells after conservation storage in SEC medium at + 4 ° C for 48 h and then primary transplantation in the immunodeficient mouse NSG. The manipulations of this study consist of different steps: Production of the graft: culture of placental blood CD34 + cells (selected by immunomagnetic screening) in a medium containing a cocktail of cytokines adapted for a duration of 12 days. At the end of the culture, the amplified cells are harvested and divided in two: a part is grafted to a batch of immunodeficient mice from which each mouse receives an amount of amplified cells produced by 1000 CD34 + cells from the culture; the other part is stored in SEC medium (PVC bag) at + 4 ° C for 48 hours and is then injected to a second batch of immunodeficient mice under the same quantitative conditions. 8 weeks after the transplant, the mice are sacrificed, human clonogenic progenitors are analyzed in the bone marrow of mice: these progenitors are generated by the stem cells (graph legend: 1 point corresponds to a mouse grafted and analyzed (CFU / femur) the dotted line corresponds to the average, the solid line corresponds to the median).
    Figure 9. Preservation yield of clonogenicity of CD34 + cells (cells of interest) of bone marrow (n = 5). CD34 + cells were banked in LN2 several years ago (3 to 6 years). After thawing, the CD34 + cells are resuspended in SEC medium and stored at 4 ° C. After 72 hours of storage at + 4 ° C., the clonogenic tests are carried out. The tests were carried out in gas-tight containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air)
    Figure 10. Preservation yield of viability and clonogenic potential of CD34 + placental blood cells. Placental CD34 + blood cells are thawed and divided into 3 aliquots: suspension of CD34 + cells in SEC medium, HP02 medium and 4% human albumin, then stored at 4 ° C. After 72 hours of storage at + 4 ° C., the analyzes (total viable nucleated nucleus count and clonogenic functional tests) are performed. The tests were carried out in gas-tight containers (polypropylene tubes of 2.5 ml capacity with 2.5 ml of cell suspension to avoid the presence of air)
    Examples
    After finding a number of active ingredients in the Codex, the inventors chose injectable pharmaceutical preparations that they associated and they made a base formulation that they then tested compared to the HP02 reference medium (Macopharma). They obtained preservation results after 48h and 72h storage at + 4 ° C virtually identical with both media.
    The inventors have therefore tested the interest of each product and sought the optimum concentration useful. Some components were excluded from the initial formulation either because of the lack of global action (SeNa), or because of a possible renal toxicity recently recognized (Hydroxy-ethyl-Starch 6%).
    The inventors have thus demonstrated the importance of vitamins E (Alpha-Tocopherol) and, to a lesser extent, vitamins A (retinoic acid) and C (ascorbic acid), K +, Mg ++, and lactate and magnesium ions. human albumin on the maintenance of viability and especially of the functionality (clonogenicity) of amplified CD34 + cells.
    In the end, the components of 12 pharmaceutical preparations are included in the formulation of the biological preservation medium. The preservation medium is sterilely prepared in a gas impermeable EVA (Ethylene vinyl acetate) pouch in such a way that the atmospheric gases, in particular the oxygen (02), can not penetrate and that especially the carbon dioxide (CO 2) dissolved during pH adjustment (action of citric acid on Na bicarbonate) remains in the medium (would promote the preservation of cells at low temperature); as a result, the pH of the medium remains at the desired value for a period of several years. These pouches are used in the pharmaceutical industry to condition injectable preparations and by suppliers of biological reagents to preserve culture media among others.
    The inventors named this SEC preservation medium.
    Description of the preservation environment
    Injectables used
    Product Cl: Human albumin solution 20% (human albumin composition 200gr, caprylic acid qsp llitre): it has a role of protection of certain molecules; it has shown in our tests a very clear role in maintaining the viability of total nucleated cells; it allows a better stability of the pH of the medium formulated in the containers not impervious to gases during the conservations of the cells amplified at + 4 ° C. (See Figure 1) Product C2: Amino Acids (Vaminolact® (Fresenius Kabi) composition qs 100ml: L-Alanine 630mg, L-Arginine 410mg, L-Aspartic Acid 410mg, L-Cysteine / L Cystine 410mg, L-Glutamic Acid 710mg Glycine 210mg, L-Histidine 210mg, L-lysoleucine 310mg, L-Leucine 700mg, L-Lysine 560mg, L-Methionine 130mg, L-Phenylalanine 270mg, L-Proline 560mg, Serine 380mg, L-Taurine 30mg; Threonine 360mg, L-Tryptophan 140mg, L-Tyrosine 50mg, L-Valine 360mg.) Amino acids provide a non-significant improvement in the functionality of the cells amplified but nevertheless interesting as some amino acids may have a protective role on cells. (See Figure 3)
    Product C3: KCI (10% preparation in H2O): It showed during our tests a significant action on the preservation of the functionality of the amplified cells. (See Figure 3) Product C4: Glucose (30% preparation): It showed in our tests a nonsignificant but interesting action. (See Figure 3)
    Product C5: Amino acid Glutamine (Dipeptiven Composition (Fresenius Kabi): Alanyl-Glutamine 20g / 100ml or 13.2g of Glutamine / 100ml, stable molecule versus glutamine): it showed during our tests a nonsignificant but interesting action; it would have a protective action on the mitochondria. (See Figure 3)
    Product C6: MgSO4 (15% preparation in H2O) It showed during our tests a significant action on the preservation of the functionality of the amplified cells; he would have a role in the mitochondria. (See Figure 4)
    C7 Products: Antioxidants ®
    That is C7.Cernevit (Baxter) (Composition for 5ml: Retinol [Vitamin A] 3500 Ul in the form of retinol palmitate; Cholecalciferol [Vitamin D3] 220 IU; Alpha-tocopherol or [Vitamin E] 11.2 IU is 10.2 mg Ascorbic acid [Vitamin C] 125 mg, Thiamine [Vitamin B1] 3.51 mg, Riboflavin [Vitamin B2] 4.14 mg); Pyridoxine [Vitamin B6] 4.53mg; Cyanocobalamin [vitamin B12] 0.006mg; Folic acid [Vitamin B9]; Pantothenic acid [Vitamin B5] 17.15mg; Biotin [Vitamin B8] 0.069mg; Nicotinamide [Vitamin PP] 46mg): It showed in our tests a preservative action of the cell function stored at + 4C; Among vitamins tested separately, vitamin E has the most important action; vitamins A and C have a lower activity, but vitamin C is described to have a protective role of vitamin E; the addition of Cernevit® to the culture supernatant showed an identical effect to the medium formulated in the preservation of the amplified cells at + 4 ° C. Finally, each vitamin exists as an injectable medicine and only vitamins E and C could be used in the formulation.
    Let C7a.Vitamin E (composition for 2ml: Alpha-tocopherol lOOmg)
    Let C7b.Vitamin C (composition for 5ml: Ascorbic acid 1000mg)
    Let C7c.Vitamin A (composition for 2ml: Retinol 100000 Ul)
    Vitamin E can be used alone or combined with vitamin C or A or the combination of both with a similar or similar effect in terms of preservation of the cells amplified to that of Cernevit®. Vitamin C would protect vitamin E. (See Figure 1, Figure 3 and Figure 6)
    Product C8: Mannitol (20% solution): it has an antioxidant role (anti-radical hydroxyl) and showed in our tests a non-significant action .. (See Figure 4)
    Product C9: Ringer Lactate (composition: NaCI 6gr, KCI 0.4gr, CaCh 2H2O 0.27gr, lactate of Na 5.16gr qsp llitre is Na + 131mmol, K + 5mmol, Ca ++, Lactate 29mmol.) It has a minor antioxidant role, a small buffer role (idem ion C03 ~) is present in the culture supernatant; he showed during our tests a relatively significant action on the preservation of the function of the amplified cells. (See Figure 3)
    CIO product: NaCl (in the form of 0.9% saline): it acts as a solute and maintains a physiological osmolarity. He showed during our tests a particular interest on the clonogenic potential because if it is replaced by an isotonic solute of glucose or mannitol, one observes, after 48h of conservation with + 4 ° C, a very important fall of the clonogenic functionality despite maintaining the viability of the total nucleated cells. (See Figure 5)
    Product Cil: Sodium bicarbonate (1.4% NaHC03 preparation) It allows to create a pseudo buffer system with citric acid of ACD A to adjust the pH of the medium to the desired value and bring dissolved CO2 (protective action on cells of interest at + 4 ° C).
    Product C12: ACD A (Citric acid Citrate Dextrose solution A) (Dextrose monohydrate 24.5g, citric acid monohydrate 8gr, sodium citrate dihydrate 22gr qs 1 liter). It adjusts the pH after addition of sodium bicarbonate; the citrate ion is described as having an antioxidant action and finally the citrate ion complex part of the calcium ions introduced into the medium with Ringer Lactate. ACD A is an anticoagulant conventionally used in transfusion practice.
    The table below gives the current formulation with interesting high and low values and active components highlighted during the optimization studies. The following components were not studied for optimization and only the physiological values were taken into account: KCI (0.33gr / l final combining KCL10% and KCI contained in Ringer Lactate), Glucose, NaCl, ACD A.
    The pH of the preferred preservative solution is 6.95 ± 0.05.
    Table 2
    Tests of the action of the components of the preservation medium 1. On the cells of his placental CD34 + selected and then amplified ex vivo.
    The cells, after ex vivo expansion, are more fragile than the original CD34 + cells and their maintenance is the most critical at + 4 ° C (Duchez et al, 2013, supra).
    During all the studies leading to the formulation of the biological preservation medium, the tests were performed on CD34 + cells of placental blood from a bank stored at -196 ° C. Each test was performed on 1 or more samples.
    CD34 + placental blood cells are isolated by an immuno-magnetic system, then frozen and stored at -196 ° C.
    After thawing, placental blood CD34 + cells (20000 / ml) are cultured in HP01 medium in the presence of SCF (Stem Cell Factor) 100 ng / ml, Flt3 (FMS-like tyrosine kinase-3) 100 ng / ml, G- Granulocyte Colony Stimulating Factor (CSF) 10 ng / ml and thrombopoietin (TPO) 20 ng / ml at 37 ° C., 5% CO 2 and 85% humidity. At mid-culture, an addition of culture medium HP01 with the cytokines (dilution to 1/5) is carried out and the culture extended to 9 to 12 days (usually 10 days). At the end of the culture, 2.5 ml of cell suspension is transferred into 2.5 ml tubes of polypropylene impermeable to gas, then centrifuged at 430 g for 10 minutes at 18 ° C. The supernatant is removed in its entirety (about 50 μΙ of culture supernatant remains on the cell pellet). Then, 2.45 ml of the preservation medium to be tested (at room temperature) are added to the tube, then the tube is closed by the stopper and the cells are resuspended by successive turns. The samples are then left at room temperature for 1 to 3 hours. Finally, the tubes are placed flat at + 4 ° C for durations in general from 48h to 72h. Tests were also conducted in gas-permeable PVC bags for comparative studies and in gas-tight EVA bags.
    Analyzes are then carried out on the amplified cells: counting and viability of the CNTs (Total Nuclear Cells) and clonogenic tests, with sometimes counting and viability of the CD34 + cells. After the passage at + 4 ° C for the defined durations (48h and 72h), the cell samples are tested: CNT count and viability and clonogenic tests (sometimes also CD34 + cell count and viability).
    The amount of viable total nucleated cells remaining after storage at 4 ° C is compared to the amount of viable total nucleated cells at the end of culture, which provides a viable cell recovery yield. Similarly, a calculation of CFC (Colony Forming Cells) yield is performed. The values obtained made it possible to evaluate the interest of one or more compounds in the formulation and then to look for the optimal concentration of these compounds. The values were compared with those obtained with the HP02 preservation medium (Duchez et al, 2013, supra).
    The results are shown in Figure 1.
    Placental CD34 + blood cells amplified ex vivo were grafted onto immunodepressed NSG mice to study the preservation of the clonogenicity of the amplified CD34 + cells after storage in SEC medium at + 4 ° C. for 48 h. The manipulations of this study consist of different steps: Production of the graft with culture of placental blood CD34 + cells (selected by immunomagnetic screening) in a medium containing a cocktail of cytokines adapted for a duration of 12 days. At the end of the culture, the amplified cells are harvested and divided in two: a part is grafted to a batch of immunodeficient mice from which each mouse receives an amount of amplified cells produced by 1000 CD34 + cells from the culture; the other part is stored in SEC medium (PVC bag) at + 4 ° C for 48 hours and is then injected to a second batch of immunodeficient mice under the same quantitative conditions. 8 weeks after the transplant, the mice are sacrificed, human clonogenic progenitors are analyzed in the bone marrow of mice: these progenitors are generated by the stem cells (graph legend: 1 point corresponds to a mouse grafted and analyzed (CFU / femur) the dotted line corresponds to the average, the solid line corresponds to the median). The results show that storage in SEC medium for 48 h at 4 ° C. does not alter the number of clonogenic progenitors derived from mouse-transplanted stem cells.
    The results are shown in Figure 8. 2. On placental blood cells after sampling
    The placental blood is taken from a plastic bag (PVC polyvinyl chloride) containing 23 ml of anticoagulant CPD (Citrate phosphate dextrose). The placental blood unit is then placed at + 4 ° C pending its treatment for banking (cryopreservation at -196 ° C). The protocol requires that banking be performed within 36 hours to avoid cellular alterations related to the mode of preservation (+ 4 ° C) and the absence of preservation media. To allow very distant samples that can respond to therapeutic interests (tissue compatibility, rare HLA phenotypes, DOM-TOM populations, etc ...) and require delivery times greater than 36 hours, a first work to improve the Placental blood unit preservation after sampling was performed. It consisted of combining a gas-impermeable pouch and the addition of non-injectable medium (MacOPharma HP02) to a placental blood unit. This has significantly improved the delay before banking (up to 72h) while maintaining a viability and functionality compatible with an effective transplant (WO 2014/057220, Chevaleyre et al, 2014, Stem Cells Dev, 23, 1820-1830).
    The HP02 medium, not being injectable, the SEC medium (according to the present invention) was used to preserve the placental blood units. After 72h of storage at + 4 ° C, the addition of SEC medium has maintained a significantly better functionality and compatible with banking (Rodriguez, Master 2 thesis, University of Bordeaux, supported June 11, 2014). The results obtained are shown in Figure 2. 3. On selected CD34 + cells of placental blood after thawing.
    The placental blood CD34 + cells frozen at -196 ° C. are thawed, washed and divided into 3 aliquots: suspension of the CD34 + cells in SEC medium, in HP02 medium and in 4% human albumin, and then stored at 4 ° C. . After 72 hours of storage at + 4 ° C., the analyzes (count of viable total nucleated cells and clonogenic functional tests) are carried out. The tests were carried out in gas impermeable containers (2.5 ml polypropylene tubes of capacity with 2.5 ml of cell suspension to avoid the presence of air as much as possible). The results show a very good preservation of CD34 + cells quantitatively (number of viable cells) and qualitatively (clonogenic functionality) after storage of 72h at + 4 ° C in SEC medium compared to HP02 medium. The results obtained are shown in Figure 10. 4. On bone marrow CD34 + cells after thawing (n = 5)
    The CD34 + medullary cells are banked (freezing at -196 ° C for 3 to 6 years), thawed, washed and resuspended in 2.5ml SEC medium 2.5ml tube impermeable polypropylene gas; they are stored at + 4 ° C for 72 hours. The clonogenic tests carried out after thawing and after 72h preservation at 4 ° C shows a good preservation of the functionality of these medullary cells of interest (preservation performance> 70%). The results obtained are shown in Figure 9. 5. On peripheral blood cells mobilized after thawing (n = 1)
    Peripheral blood cells following Ficoll gradient (CM) were frozen at -196 ° C. After thawing and washing, they are separated into 2 aliquots: the first is left as is and the second undergoes an immunomagnetic separation which will make it possible to obtain a suspension of CD34 + cells. The CMN cells and the CD34 + cells are suspended in SEC medium (2.5 ml) in 2.5 ml polypropylene tubes impermeable to gases and then stored at + 4 ° C. for 48 to 120 hours. Clonogenic tests carried out after thawing of CMNs and / or purification of CD34 + cells and then after storage at 4 ° C. show good preservation of the functionality of these cells of interest: 85% functional preservation yield (purified CD34 + cells) at 100% (CMN) after 48h at + 4 ° C and 60% (80% purified CD34 + cells) (CMN) after 120h at 4 ° C. The results obtained are shown in Figure 7.
    权利要求:
    Claims (12)
    [1" id="c-fr-0001]
    claims
    A solution for storing placental blood, bone marrow and peripheral blood cells, characterized in that it comprises a physiological solution of sodium chloride, potassium chloride, magnesium sulphate, sodium bicarbonate, vitamin E and / or A, and human albumin, and that it is injectable.
    [2" id="c-fr-0002]
    2- injectable solution according to claim 1, comprising at least 5 g / l of human albumin and 0.000025 g / l of vitamin E and / or 0.0000026 g / l of vitamin A.
    [3" id="c-fr-0003]
    3- Injectable solution according to claim 1 or 2, further comprising lactate and vitamin C.
    [4" id="c-fr-0004]
    4- Injectable solution according to any one of claims 1-3, comprising at least 0.0003 g / l of vitamin C.
    [5" id="c-fr-0005]
    5- Injectable solution according to any one of claims 1-4, further comprising one or more elements selected from amino acids including glutamine, glucose, mannitol and citric acid.
    [6" id="c-fr-0006]
    6- Injectable solution according to any one of claims 1-5, characterized in that it comprises or consists of a physiological solution of sodium chloride, human albumin, vitamins E, C and A, amino acids including glutamine, potassium and magnesium ions, glucose, mannitol, lactate, sodium bicarbonate and citric acid.
    [7" id="c-fr-0007]
    7- Kit comprising the injectable preservation solution according to any one of claims 1-6 and a sterile container for receiving cells of placental blood, bone marrow and peripheral blood.
    [8" id="c-fr-0008]
    8- sterile container for receiving cells of placental blood, bone marrow and peripheral blood, characterized in that it comprises the injectable preservation solution according to any one of claims 1-6.
    [9" id="c-fr-0009]
    9- container according to claim 8, characterized in that it further comprises placental blood cells, bone marrow and peripheral blood, the cells not being human embryonic cells.
    [10" id="c-fr-0010]
    Use of the solution for injection according to any of claims 1-6, a kit according to claim 7 or a container according to claim 8 for storing placental blood, bone marrow and blood cells. peripheral, preferably in moderate hypothermia, especially at 4 ° C.
    [11" id="c-fr-0011]
    11. A method for preserving placental blood, bone marrow and peripheral blood cells, comprising contacting the cells of the placental blood, bone marrow and peripheral blood with the solution for injection according to any one of the claims. 1-6, the cells not being human embryonic cells.
    [12" id="c-fr-0012]
    12- container according to claim 9, use according to claim 10 or method according to claim 11, characterized in that the cells comprise CD34 + cells.
    类似技术:
    公开号 | 公开日 | 专利标题
    CA2887583C|2021-03-23|Method for preserving placental blood
    AU2009228056B2|2015-03-12|Materials and methods for hypothermic collection of whole blood
    EP3346833A1|2018-07-18|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood
    EP2713716B1|2016-08-24|Organ-preserving composition comprising an extracellular hemoglobin from arenicolidae and uses therefof
    JP2000516963A|2000-12-19|Erythrocyte long-term preservation method using oxygen removal and additives
    US9402388B2|2016-08-02|Methods of freezing stem cells
    EP1909565A2|2008-04-16|Somatic cells for use in cell therapy
    CN106665559B|2018-01-09|A kind of immunocyte frozen stock solution and its application
    EP3316684B1|2019-09-18|Method for the cryopreservation of cells for therapeutic purposes
    EP3316895B1|2019-09-18|Method for the cryopreservation of cells for therapeutic purposes
    US9315775B2|2016-04-19|Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
    RU2632979C2|2017-10-11|Method for erythrocytes preservation
    CA3115973A1|2020-04-16|Oxygenation media for ex-vivo preservation of organs and tissues
    Gaucher et al.2010|Viability and efficacy of coverage of cryopreserved human skin allografts in mice
    Lee et al.2005|The effect of human serum albumin on the extended storage of human oral keratinocyte viability under mild hypothermia
    CA2710181C|2017-02-28|Method for preserving sperm and applications thereof
    CN112998009A|2021-06-22|NK cell cryopreservation liquid and preparation method and application thereof
    US20130143196A1|2013-06-06|Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
    EP3589298A1|2020-01-08|Mesenchymal stem cells obtained from wharton's jelly for the treatment of sepsis
    EP3716762A1|2020-10-07|Method for the cryopreservation of cells for therapeutic purposes
    Donmez et al.2007|Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation
    WO2021183653A1|2021-09-16|Compositions for extending viable preservation and shelf-life of organs and tissues
    同族专利:
    公开号 | 公开日
    RU2017142903A3|2020-01-14|
    HK1250604A1|2019-01-11|
    RU2017142903A|2019-06-10|
    WO2017042501A1|2017-03-16|
    CA2986267A1|2017-03-16|
    EP3346833A1|2018-07-18|
    US20180184643A1|2018-07-05|
    RU2727643C2|2020-07-22|
    FR3040860B1|2020-05-15|
    CN108135154A|2018-06-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1995029230A1|1994-04-20|1995-11-02|Diacrin, Inc.|Culture medium for maintaining viability of mammalian cells|
    WO1997041848A1|1996-05-08|1997-11-13|The Government Of The United States, Represented By The Secretary Of The Army|Pharmaceutical compositions containing alpha-keto carboxylates|
    WO2001052647A1|2000-01-20|2001-07-26|Res-Del International Limited|Physiological medium for perfusing, preserving and storing isolated cell, tissue and organ samples|
    WO2002035929A1|2000-11-03|2002-05-10|Vitrolife Ab|Evaluation and preservation solution|
    WO2008131973A2|2007-04-26|2008-11-06|Medinnova As|Transplant storage|FR3101538A1|2019-10-07|2021-04-09|Action Vitale|Composition of physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.|US6153582A|1998-11-05|2000-11-28|Bausch & Lomb Surgical, Inc.|Defined serumfree medical solution for ophthalmology|
    EP1482787A4|2002-02-13|2006-02-15|Anthrogenesis Corp|Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells|
    RU2188654C1|2001-12-13|2002-09-10|Государственное некоммерческое учреждение Гематологический научный центр РАМН|Blood preparations and method for producing them|
    CN1772882A|2004-10-12|2006-05-17|尼普洛株式会社|Cell-preservation liquid,and preparing method thereof,cell preservation method and cell culturing method|
    DE102005049226B4|2005-10-14|2007-08-02|Technische Universität München|Sampling system for fluid samples|
    RU2311027C1|2006-05-11|2007-11-27|Институт физиологии Коми научного центра Уральского отделения Российской Академии Наук|Solution for leukocyte preservation at near-zero temperature|
    ITUD20080058A1|2008-03-18|2009-09-19|Thankstem S R L|PREFERIBLY PERIPHERAL BLOOD COLLECTION KIT, FOR THE PRODUCTION OF STEM CELLS|
    SG178358A1|2009-08-11|2012-03-29|Genentech Inc|Production of proteins in glutamine-free cell culture media|
    WO2011037913A2|2009-09-24|2011-03-31|Emory University|Methods for preventing oxidative stress injury of a tissue by a folate-tempol conjugate|
    FR2996413B1|2012-10-10|2014-12-05|Maco Pharma Sa|METHOD FOR PRESERVING PLACENT BLOOD|FR3035407A1|2015-04-23|2016-10-28|Francais Du Sang Ets|METHOD FOR PRESERVING CELLS, TISSUES OR ORGANS IN HYPOTHERMIA|
    FR3088541B1|2018-11-15|2021-11-05|Lab Francais Du Fractionnement|CELL CONSERVATION PROCESS FOR THERAPEUTIC AIMS|
    法律状态:
    2016-09-09| PLFP| Fee payment|Year of fee payment: 2 |
    2017-03-17| PLSC| Search report ready|Effective date: 20170317 |
    2017-09-21| PLFP| Fee payment|Year of fee payment: 3 |
    2018-02-16| TQ| Partial transmission of property|Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR Effective date: 20180116 Owner name: UNIVERSITE DE BORDEAUX, FR Effective date: 20180116 |
    2018-09-25| PLFP| Fee payment|Year of fee payment: 4 |
    2019-09-20| PLFP| Fee payment|Year of fee payment: 5 |
    2020-09-21| PLFP| Fee payment|Year of fee payment: 6 |
    2021-09-13| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1558409|2015-09-10|
    FR1558409A|FR3040860B1|2015-09-10|2015-09-10|INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS|FR1558409A| FR3040860B1|2015-09-10|2015-09-10|INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS|
    RU2017142903A| RU2727643C2|2015-09-10|2016-09-09|Injectable preservative medium for preserving placental blood cells, bone marrow and peripheral blood|
    CN201680033782.6A| CN108135154A|2015-09-10|2016-09-09|For preserving the injectable Storaged media of the cell from placental blood, from marrow and from peripheral blood|
    EP16777718.4A| EP3346833A1|2015-09-10|2016-09-09|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood|
    PCT/FR2016/052253| WO2017042501A1|2015-09-10|2016-09-09|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood|
    CA2986267A| CA2986267A1|2015-09-10|2016-09-09|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood|
    US15/580,699| US20180184643A1|2015-09-10|2016-09-09|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood|
    HK18110115.9A| HK1250604A1|2015-09-10|2018-08-07|Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood|
    [返回顶部]